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Abstract
Objective: To study the influence of pharmacological psychocorrection with drugs derived from GABA on the quality of life 
of primary school-aged children with functional dyspepsia.
Materials and methods. 80 children aged 6–12 years with FD have been examined. Children were divided into 4 groups: 
Group 1 – 20 patients who received γ-amino-β-phenylbutyric acid hydrochloride along with baseline therapy, Group 2 – 20 patients 
who received comprehensive treatment and calcium hopantenate, Group 3 – 20 children who received vitamin-mineral complex and 
protocol treatment, and Control Group – 20 children who received baseline treatment. Study Design: general clinical, instrumental, 
psychodiagnostic, statistical.
Results. Using the PedsQL questionnaire, physical functioning disorders were found in children with FD – 97.5 ± 1.2 % (78/80) 
of children, emotional functioning disorders – 91.3 ± 1.6 % (73/80) of cases, functioning at school disorders – 88.8 ± 2.7 % (71/80) of 
patients. During one-month case monitoring, children who took GABA drugs reported an improvement in the quality of life com-
pared with baseline treatment and a group of children, who took a mineral-vitamin complex: physical functioning – (р1 = 0.016), 
(р2 = 0.03), emotional functioning – (р1 ˂ 0.001), (р2 ˂ 0.001), functioning in school – (р1 = 0.005), (р2 = 0.004).
Conclusion. The use of γ-aminobutyric acid drugs is safe and effective and they significantly improve the quality of life of 
children with FD.
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1. Introduction
Functional dyspepsia (FD) is a functional gastrointestinal disorder (FGID), which is one of 
the dominants in the Rome classifications from the beginning of their creation. FD is manifested 
by constant or recurrent abdominal pain upper and, according to the Rome IV criteria, is assigned 
to group B – gastroduodenal disorders [1, 2]. The prevalence of FD according to various studies 
varies from 1.4 % to 30 % [3, 4].
The authors believe that the FGID significantly affects the quality of life of children [5, 6], 
modulates the nature and intensity of clinical symptomatology, patient behaviour, his/her emotio-
nal state and social functioning [7, 8].
The issue of the advisability of long-term administration of drugs to such patients that affect 
the function of the central nervous system is being constantly debated in the scientific literature [4, 7]. 
Therapy with tricyclic antidepressants (amitriptyline, imipramine) has proven its effectiveness in 
complex cases, but its common use is limited by a significant number of side effects [4, 9]. The 
advisability of psychotherapeutic correction in case of functional dyspepsia, like other forms of 
FGID, is considered, which requires active training of relevant specialists in Ukraine and the de-
velopment of the psychotherapeutic care system in general [10, 11].
So, the issue of finding effective means and correcting psychoemotional disorders and quality 
of life in children with functional gastrointestinal disorders and, in particular, functional dyspepsia 
continues to be relevant.
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Since several studies have shown an increase in the activity of excitatory amino acids in 
children with FGID [12, 13] special attention in the aspect of psychocorrection shall be paid to 
ɣ-aminobutyric acid (GABA) drugs [14, 15]. GABA is a natural metabolite with the functions of 
an inhibitory neurotransmitter, which favourably affects the energy of the neuron, neurodyna-
mics, and cerebral circulation [16, 17]. Thus, a combination of soothing and mild psychostimu-
lating effects is achieved. In its pure form, exogenously introduced GABA does not penetrate the 
blood-brain barrier (BBB) [18], which intensified the need for the creation of several complex com-
pounds [9, 12]. In our opinion, γ-amino-β-phenylbutyric acid hydrochloride (Phenibut) and calcium 
hopantenate are of great interest to the FD treatment [11].
Objective. To study the influence of pharmacological psychocorrection with drugs derived 
from GABA on the quality of life of primary school-aged children with functional dyspepsia.
2. Materials and methods
During 2016–2017 80 children aged 6–12 years (38 boys and 42 girls) who sought help from the 
Kyiv City Children’s Clinical Hospital No. 1 with complaints which, according to the Rome IV criteria, 
met the diagnosis of functional dyspepsia, have been examined. The study was approved by the 
committee on bioethics of the Shupyk National Medical Academy of Postgraduate Education (pro-
tocol No. 2 of 10.01.2017) and was carried out in accordance with the guidelines of the Helsinki 
Convention, 1975. All participants and their parents were fully informed about the methods and 
scope of the study and gave written informed consent for participation. 
The inclusion criteria in the study were: the presence of voluntary informed consent of 
the child parents to participate in clinical trials; the age of patients varies from 6 to 12 years; the 
presence of a functional dyspepsia diagnosis; the absence of clinical and laboratory signs of or-
ganic lesion of GIT. The exclusion criteria from the study were: refusal of the patient’s parents to 
participate in a clinical trial; the presence of anxiety symptoms; detection of signs of an inflam-
matory, metabolic, neoplastic process, anatomical defects that could explain the onset of dyspepsia 
symptoms during the examination; the presence of chronic diseases of the gastrointestinal tract; 
the presence of mental illnesses; the presence of severe diseases of the child of any localization; 
taking drugs that affect the functional activity of the central and autonomic nervous system; failure 
to comply with study requirements.
All children underwent a set of diagnostic procedures in accordance with the Unified Clini-
cal Protocol of Medical Aid for Children with FD (Order of the Ministry of Health of Ukraine No. 59 
dated January 29, 2013) and the local protocol: general work-up, EGD, determination of H. pylori 
antigen in feces, Ultrasonography of the abdominal organs to exclude concomitant pathology [10].
Quality of life assessment was carried out using the «Paediatric Quality of Life Inventory», 
«PedsQL»), which consists of 23 statements, grouped on 4 scales: health, emotional and physical 
well-being, labour productivity, relationships with others. The rate of disorders was assessed in 
points: 1 – «I never feel», 2 – «almost never», 3 – «sometimes», 4 – «often», 5 – «almost always» [8].
To assess the quality of life in the comprehensive treatment of FD, children were divided into 
4 groups by simple randomization: 3 experimental and 1 control group with 20 patients each. The 
groups were comparable by sex, age, clinical options for FD, and the morbidity. All children received 
treatment according to the Unified Clinical Protocol of Medical Aid for Children with FD (Order of 
the Ministry of Health of Ukraine No. 59 dated January 29, 2013) and the local protocol (correction 
of the day regimen and diet, antacid, antisecretory drugs, prokinetics) [4]. Children of the first group 
received γ-amino-β-phenylbutyric acid hydrochloride as part of a comprehensive treatment at a dose 
of 100 mg t.i.d. for 1 month; children of the second group received a calcium salt of hopantenic acid 
as part of a comprehensive treatment at a dose of 125 mg (1/2 tablet) t.i.d. for 1 week; at a dose of 
250 mg t.i.d. for 45 days; at a dose of 125 mg (1/2 tablet) t.i.d. for 1 week (total 2 months); at a dose 
of 250 mg q.i.d. for a month; children of group 3 received a complex of organic compounds of mag-
nesium and B6 vitamin as part of a comprehensive treatment at a dose of 1 tablet q.i.d. for 1 month.
The clinical dynamics of the manifestations during treatment was assessed on the 3rd, 7th, 








Statistical processing of the obtained data was carried out with the calculation of parametric 
and nonparametric criteria using standardized tools of Microsoft Excel 2010 and the R program-
ming language for statistical data processing [19]. In the article, the data obtained are presented 
in the form of relative values and their deviations (M ± m), absolute values from which the rela-
tive values are calculated, in n/N format, where n is the number of cases and N is the size of the 
corresponding group. Since the quantitative characteristics had a predominantly nonparametric 
distribution, they are presented in the Me format [QR: 25 %; 75 %], where Me is the median, QR is 
the quartile range. The normality of distribution was determined by the Kolmogorov-Smirnov and 
Shapiro-Wilk criteria, and the Smirnov-Grabs test was also carried out to determine gross errors 
of normally distributed data. The power of the sample is represented as (π), with the generally ac-
cepted π = 0.80, which was determined using the T-test. When comparing the dependent variables, 
since their distribution was nonparametric, the Wilcoxon T-test was used, and when comparing the 
independent variables – the nonparametric Kruskal-Wallis test. The difference between the values 
was considered statistically significant when the test significance level was p < 0.05.
3. Results
The main complaint of the children who participated in the study was abdominal pain, which 
by definition is the main diagnostic criterion for functional dyspepsia. A comparison of complaints 
with the Rome III and IV criteria made it possible to establish the presence of epigastric pain syn-
drome in 42.5 ± 0.5 % (34/80) of children, postprandial distress syndrome – in 57.5 ± 1.2 % (46/80) 
of examined patients. The average age of the children participating in the study was 10 years. The 
power of the sample was π = 0.712, which is slightly less than the generally accepted value (π = 0.80).
Quality of life assessment carried out using the PedsQL questionnaire, demonstrated the 
presence of disorders of physical functioning in all examined children. The highest score was 
obtained for the sense of pain – in 97.5 ± 1.2 % (78/80) of the examined patients, feeling weak – in 
86.3 ± 2.2 % (69/80). A low energy level was also determined in 81.3 ± 2.4 % (65/80) of children. 
Thus, the median of indicators for the «physical functioning» block equaled 5 points [QR: 4; 5], 
which indicates a high level of disorders. According to the questionnaire data, children had fre-
quent disorders in the field of emotional functioning – 5 points [QR: 4; 5]: most often, children were 
worried about a sense of fear for their health – in 91.3 ± 1.6 % (73/80) of cases and loss of sleep (poor 
falling asleep, troubled sleep), which was reported by 77.5 ± 2.2 % (62/80) of patients. The ex-
amined children had problems with functioning at school as well: the median of the assessment 
equaled 5 [QR: 4; 5], which corresponds to the «I feel problems very often» statement. Children’s 
problems were associated with their absence at school due to sickliness in 88.8 ± 2.7 % (71/80) 
of patients and due to the need to see a doctor in 66.3 ± 1.7 % (53/80) of the examined patients. The 
level of problems with the social functioning block equaled 2 points [QR: 2; 3], which corresponds 
to the «sometimes I feel problems» statement.
After 1 month, when testing under the PedsQL questionnaire, children of the four groups 
reported an improvement in the quality of life. So, children, who received Phenibut, had physical 
functioning disorders with an intensity of 1 point [QR: 1; 1.25], which corresponds to the «I never 
have problems» statement, versus 5 points [QR: 4; 5] before treatment (p1 = 0.005), the intensi-
ty of the physical functioning disorders in children in the control group after 1 month equaled 
2 points [QR: 1; 2] versus 5 points [QR: 4; 5] before treatment (p1 = 0.063), the children who took 
organic magnesium compounds as part of the comprehensive treatment, reported an improvement 
in this block of questions after treatment as well – 2 points [QR: 1.5; 3] versus 5 points [QR: 4; 5] 
before treatment (p = 0.056). The group of patients who took calcium hopantenate after treatment 
assessed the physical functioning disorders according to the «I never feel a problem» statement 
compared to the same option before treatment (p = 0.013). When comparing groups with each oth-
er, statistically better results in a month after treatment were found in groups taking GABA de-
rivatives: thus, the physical functioning disorders in children taking Phenibut was significantly 
less than in the control group (p = 0.016). Children from the calcium hopantenate group assessed 
physical functioning disorders after treatment as 1 point [QR: 1; 2], statistically different from the 
control group (p = 0.03) (Fig. 1).
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Fig. 1. Physical functioning
After 1 month, children from the Phenibut group did not report emotional functioning disor-
der – 1 point [QR: 1; 1] versus 5 points [QR: 4; 5] before treatment (p = 0.016) and 3 points [QR: 2; 3] 
in children of the control group (p ˂ 0.001). No differences have been found one month after treat-
ment between the group taking calcium hopantenate and the group taking Phenibut (p = 0.178). 
Also, the Phenibut group showed the best results 1 point [QR: 1; 1] versus 2 points [QR: 1.5; 3] 
of the group taking the vitamin-mineral complex (p = 0.009). The emotional functioning of child-
ren taking calcium hopantenate in a month equaled 1 point [QR: 1; 2], which corresponds to the 
«I never have problems» statement, versus 5 points [QR: 4; 5] before treatment (p = 0.032) and 
3 points [QR: 2; 3] of the control group (p ˂ 0.001). No differences have been found between the 
group taking calcium hopantenate and mineral-vitamin complex (p = 0.078). Children who took mine-
ral-vitamin complex, emotional functioning equaled 2 points [QR: 1.5; 3] versus 5 points [QR: 4; 5] 
before treatment (p = 0.059) and 3 points [QR: 2; 3] of the control group (p = 0.04) (Fig. 2).
Fig. 2. Emotional functioning
The functioning at school in patients taking Phenibut 1 month after treatment equaled 
1.5 points [QR: 1; 2], which corresponds to the «I never have problems» statement, versus 
5 points [QR: 4; 5] before treatment (p = 0.003), which corresponds to the «I feel problems very 
often» statement and versus 2.5 points [QR: 2; 3] of the control group (p = 0.005) 2 points [QR: 2; 3] 
of the group taking the vitamin-mineral complex (p = 0.032). No differences in this block of ques-
tions have been found at the group taking calcium hopantenate (p = 0.936). Results on the func-
tioning at school scale in patients taking calcium hopantenate, 1 month after treatment, equaled 
1 point [QR: 1; 2] versus 5 points [QR: 4; 5] before treatment (p = 0.044), also this indicator was 
statistically lower when compared with the control group (p = 0.004) and the group taking the min-
eral-vitamin complex (p = 0.032). No differences in functioning at school improvement one month 
after treatment have been found at the group taking the vitamin-mineral complex. There was also 
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Fig. 3. Functioning at school
4. Discussions
The results of this study showed that patients with PD have significant impairments in quali-
ty of life in all areas of functioning, noted Varni et al., But we did not conduct psychological testing 
to detect depression and anxiety, which requires further study in combination with quality of life 
children [5, 8]. Tyurenkov and co-authors experimentally investigated and proved that GABA de-
rivatives have a prophylactic effect in chronic psychoemotional stress [16, 17] and have a positive 
effect on the quality of life of patients [11, 16], which was noted in our study. GABA derivatives 
combine the properties of a neuroprotector and an anxiolytic [15, 17], so they can be used in the 
treatment of PD in children. As noted by MV Khaitovich in one study, GABA derivative therapy 
proved its effectiveness in schoolchildren with autonomic dysfunction: improved well-being, in-
creased efficiency, anxiety and significantly improved, which is confirmed by the results of our 
study, but requires further deep study [12, 17].
Study limitations. The study was not conducted in case of identified concomitant patho-
logy of another organs and in case of patients refuse to participate in the study. 
Prospects for further research. Future studies on this issue should be randomized placebo- 
controlled, as well as in comparison with cognitive-behavioral therapy and in larger groups of pa-
tients with the calculation of cost-effectiveness.
5. Conclusion
1. Children with functional dyspepsia have a constant component of the clinical picture, 
along with gastroduodenal complaints, there is a violation of quality of life, namely physical and 
emotional dysfunction, as well as dysfunction at school, which occurs as a result of stress.
2. Inclusion in the complex therapy of functional dyspepsia of GABA drugs can signifi-
cantly improve the quality of life of patients, their physical and emotional functioning and improve 
school performance.
3. The use of GABA drugs did not cause side effects and was well tolerated by the examined 
children, which indicates a high level of safety of this therapeutic approach.
4. The only possible disadvantage of this study is the somewhat insufficient statistical pow-
er, which indicates the need for further in-depth study of the use of GABA derivatives in the treat-
ment of PD.
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